伊克泽珠单抗
医学
银屑病
安慰剂
随机对照试验
皮肤病科
临床试验
性器官
内科学
银屑病性关节炎
病理
遗传学
生物
替代医学
塞库金单抗
作者
Lyn Guenther,Alison Potts Bleakman,Jamie Weisman,Yves Poulin,Lynda Spelman,Russel Burge,J. Erickson,Kristin Todd,Clinton C Bertram,Caitriona Ryan
标识
DOI:10.2340/00015555-3353
摘要
Ixekizumab was efficacious in treating moderate-to-severe genital psoriasis over 12 weeks. We evaluated the long-term efficacy and safety of ixekizumab for up to 52 weeks. Patients were randomized to 80 mg ixekizumab every 2 weeks or to placebo through Week 12, then received 80 mg open-label ixekizumab every 4 weeks through Week 52. In patients initially randomized to ixekizumab, clear or almost clear genital skin was achieved for 73% of patients at Week 12 and 75% at Week 52. Persistent improvements were also observed for overall psoriasis, genital itch, and the impact of genital psoriasis on the frequency of sexual activity. The safety profile was consistent with studies of ixekizumab in patients with moderate-to-severe plaque psoriasis. Ixekizumab provided rapid and persistent improvements in the signs and symptoms of genital psoriasis for up to 52 weeks of treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI